Cancer therapeutic - Ceolia Pharma/NanoCarrier
Latest Information Update: 28 Jul 2021
At a glance
- Originator CEOLIA Pharma
- Developer CEOLIA Pharma; NanoCarrier
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in Japan